世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

遺伝子治療の市場規模、シェア、動向分析レポート:適応症別(急性リンパ芽球性白血病、大細胞型B細胞リンパ腫)、ベクタータイプ別(レンチウイルス)、地域別、セグメント別予測、2023~2030年


Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Region, And Segment Forecasts, 2023 - 2030

遺伝子治療市場の成長・トレンド Grand View Research, Inc.の新しいレポートによると、世界の遺伝子治療市場は、2023年から2030年にかけて19.1%のCAGRを記録し、2030年までに294億7000万米ドルに達すると予想... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年1月4日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
180 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

遺伝子治療市場の成長・トレンド

Grand View Research, Inc.の新しいレポートによると、世界の遺伝子治療市場は、2023年から2030年にかけて19.1%のCAGRを記録し、2030年までに294億7000万米ドルに達すると予想されています。市場の発展は、遺伝子療法に基づく発見の増加、この分野への投資の増加、遺伝子療法製品の認可の上昇に起因しています。WHOによると、2025年までに毎年10〜20の新しい細胞療法と遺伝子療法が承認されると予想されています。

組換えDNA技術の継続的な開発により、今後数年間は遺伝子治療の効率が高まると予想される。また、遺伝子組換え技術の進歩により、遺伝子治療の臨床試験件数が増加すると予想されています。主に、これらの進歩は、製品の研究開発を強化するための様々な遺伝子編集ツールや発現システムとの関連で行われています。CRISPR/Cas9ヌクレアーゼ、ZFN、TALENの登場により、簡単かつ正確にゲノムを編集することが可能になりました。その結果、近年、遺伝子編集分野では多くの研究活動が行われており、遺伝子治療市場の成長に影響を及ぼすと予想されています。

遺伝子治療市場の成長は、癌の有病率の増加から大きな恩恵を受けると予想されます。がん患者および関連する死亡者数の年間増加が続いていることから、強固な治療ソリューションの開発が不可欠であることが強調されています。2020年には、世界中で約1810万人のがん患者が新たに発生しました。 9.そのうち300万人が男性で、880万人が女性です。腫瘍遺伝子研究の継続的な発展により、がんに関連する分子シグネチャーに関する実質的な情報がもたらされ、ひいてはがん治療薬の臨床試験を支援することが期待されます。

強固な疾病治療療法への需要が高まる中、各社は、疾病の原因をゲノムレベルで特定する効果的な遺伝子治療法の研究開発を加速することに注力しています。.さらに、米国FDAは、製品製造に関する多くの政策を通じて、この分野のイノベーションを常にサポートしています。2020年1月、同局は安全で効率的な製品の製造と臨床開発に関する6つの最終ガイドラインを発表しました。

さらに、細胞療法や遺伝子療法のための施設拡張は、遺伝子治療市場の成長を促進する主要な要因の1つです。遺伝子治療製造のためのいくつかの自社施設やCDMOは、生産能力を高めるための投資を始めており、その結果、市場プレイヤーにとって有利な機会を生み出すと予想されます。例えば、2022年4月、FDAはノバルティスのノースカロライナ州ダーラムのサイトに対する商業ライセンス認可を承認しました。この承認により、170,000平方フィートの施設は、市販のゾルゲンマの製造、試験、発行、および現在および今後の臨床試験用の治療薬の製造が許可されました。

遺伝子治療市場レポートハイライト

- ベクタータイプ別では、AAVセグメントが予測期間中に急成長すると予想されています。AAVは遺伝子治療のための一般的なベクターであり、世界で実施されているウイルスベクターによる遺伝子治療研究の24.0%のシェアを占めています。この間、AAVベクターを用いた臨床研究の数は急速に拡大しました。

- さらに、レトロウイルスは、ウイルスの分離とDNAの組み込みが容易であることから、2022年に大きな市場シェアを占めた

- 適応症別では、脊髄性筋萎縮症(SMA)が市場を支配しています。Zolgensmaの開発により、疾患の表現型の変化とともに、SMAの治療における有効性が大きく証明されました。2019年5月、ノバルティスはSMAの根本原因に対処することを目的としたZolgensmaの承認をFDAから取得した

- 遺伝性網膜疾患分野は、遺伝性網膜疾患を含む眼疾患の治療に用いられる遺伝子治療薬の研究開発活動の増加により、予測期間中に最も速い年平均成長率で拡大すると予想されます。Luxturnaは、遺伝性網膜疾患の治療薬として、米国ではスパーク・セラピューティクス社が、米国外ではノバルティス社が販売している。

- 北米は、臨床試験による収益と承認済み製品のリストという点で、主要な市場となっている。細胞治療の開発を促進するための強力な規制の枠組みや、この地域に相当数のバイオテクノロジー企業が存在することなどの要因を考慮し、いくつかのスポンサーや政府機関が大規模な投資を行っている。

- アジア太平洋地域は、予測期間中に大きな成長を遂げると予想されています。これは、遺伝子治療の採用率の増加、政府による投資の増加、主要企業の存在によるものと考えられます。



ページTOPに戻る


目次

Table of Contents

Chapter 1 Executive Summary
1.1 Market Summary
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Model
2.3.1 Historic And Base Year Estimates
2.3.2 Forecast Analysis
2.3.3 Study Of Approved Therapies By Disease Incidence
2.3.4 Study Of Approved Therapies By Vector
2.3.5 Region-Wise Approval
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Robust Gene Therapy Pipeline
3.3.1.2 Introduction Of Technological Advancements
3.3.1.3 Increasing Investment From Companies And Partnerships
3.3.1.4 Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
3.3.2 Market Restraint Analysis
3.3.2.1 Absence Of Effective Diagnosis Framework
3.3.2.2 High Prices Of Gene Therapy
3.3.3 Market Opportunity Analysis
3.3.3.1 Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
3.3.3.2 Facility Expansion For Cell And Gene Therapies
3.3.3.3 Technological Advancements In Manufacturing Vectors
3.3.4 Challenge Analysis
3.3.4.1 Production capacity challenges
3.3.4.2 Manufacturing challenges about large-scale production of vectors
3.4 Regulatory Framework
3.5 Major Deals & Strategic Alliances Analysis
3.5.1 Mergers & Acquisitions
3.5.2 Collaborations & Partnerships
3.6 Pipeline Analysis
3.7 Payment & Pricing Models
3.7.1 Payment Models For Innovative Therapies
3.8 Swot Analysis, by factor (Political & legal, economic, and technological)
3.9 Porter’s Five Forces Analysis
3.10 Number of Gene Therapy Doses Sold in 2022
3.11 Number of Patients Treated with Gene Therapy, 2022
Chapter 4 COVID-19 Impact Analysis
4.1 Key Market Initiatives
4.2 Conclusion
Chapter 5 Indication Business Analysis
5.1 Gene Therapy Market: Indication Movement Analysis
5.2 Acute Lymphoblastic Leukemia (ALL)
5.2.1 Global Gene Therapy Market For Acute Lymphoblastic Leukemia (All), 2018 - 2030 (USD Million)
5.2.2 Global Acute Lymphoblastic Leukemia (All) Patients Treated With Gene Therapy, 2018 - 2030
5.3 Inherited Retinal Disease
5.3.1 Global Gene Therapy Market For Inherited Retinal Disease, 2018 - 2030 (USD Million)
5.3.2 Global Inherited Retinal Disease Patients Treated With Gene Therapy, 2018 - 2030
5.4 Large B-Cell Lymphoma
5.4.1 Global Gene Therapy Market For Large B-Cell Lymphoma, 2018 - 2030 (USD Million)
5.4.2 Global Large B-Cell Lymphoma Patients Treated With Gene Therapy, 2018 - 2030
5.5 Adenosine Deaminase (Ada)‐Deficient Severe Combined Immunodeficiency (Scid)
5.5.1 Global Gene Therapy Market For Ada-Scid, 2018 - 2030 (USD Million)
5.5.2 Global Ada-Scid Patients Treated With Gene Therapy, 2018 - 2030
5.6 Melanoma (Lesions)
5.6.1 Global Gene Therapy Market For Melanoma (Lesions), 2018 - 2030 (USD Million)
5.6.2 Global Melanoma (Lesions) Patients Treated With Gene Therapy, 2018 - 2030
5.7 Beta-Thalassemia Major/Sickle Cell Disease (Scd)
5.7.1 Global Gene Therapy Market For Beta Thalassemia Major/Sickle Cell Diseases, 2018 - 2030 (USD Million)
5.7.2 Global Beta Thalassemia Major/Sickle Cell Diseases Patients Treated With Gene Therapy, 2018 - 2030
5.8 Head & Neck Squamous Cell Carcinoma
5.8.1 Global Gene Therapy Market For Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
5.8.2 Global Head & Neck Squamous Cell Carcinoma Patients Treated With Gene Therapy, 2018 - 2030
5.9 Peripheral Arterial Disease
5.9.1 Global Gene Therapy Market For Peripheral Arterial Disease, 2018 - 2030 (USD Million)
5.9.2 Global Peripheral Arterial Disease Patients Treated With Gene Therapy, 2018 - 2030
5.10 Spinal Muscular Atrophy (Sma)
5.10.1 Global Gene Therapy Market For Spinal Muscular Atrophy (Sma), 2018 - 2030 (USD Million)
5.10.2 Global Spinal Muscular Atrophy (Sma) Patients Treated With Gene Therapy, 2018 - 2030
5.11 Others
Chapter 6 Vector Type Business Analysis
6.1 Gene Therapy Market: Vector Type Movement Analysis
6.2 Gene Therapy Market: Vector Movement Analysis
6.3 Lentiviral Vectors
6.3.1 Global Lentivirus-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.4 Adeno-Associated Viral (Aav) Vectors
6.4.1 Global Aav-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.5 Retrovirus Vectors
6.5.1 Global Retrovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.6 Modified Herpes Simplex Virus
6.6.1 Global Modified Herpes Simplex Virus Vectors -Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.7 Adenovirus Vectors
6.7.1 Global Adenovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.8 Non-Viral Plasmid Vector
6.8.1 Global Non-Viral Plasmid Vector-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.9 Others
6.9.1 Global Others-Based Gene Therapy Market, 2018 - 2030 (USD Million)
Chapter 7 Regional Business Analysis
7.1 North America
7.1.1 Swot Analysis
7.1.1.1 North America Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2 Europe
7.2.1 Swot Analysis
7.2.1.1 Europe Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3 U.K.
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.10 Rest Of Europe Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3 Asia Pacific
7.3.1 Swot Analysis
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Target Disease Prevalence
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.2.5 Japan Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3 China
7.3.3.1 Target Disease Prevalence
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.3.5 China Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4 India
7.3.4.1 Target Disease Prevalence
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.4.5 India Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5 South Korea
7.3.5.1 Target Disease Prevalence
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.5.5 South Korea Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6 Australia
7.3.6.1 Target Disease Prevalence
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.6.5 Australia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7 Thailand
7.3.7.1 Target Disease Prevalence
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.7.5 Thailand Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8 Rest Of Asia Pacific Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4 Latin America
7.4.1 Swot Analysis:
7.4.2 Key Regional Dynamics
7.4.2.1 Latin America Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3 Brazil
7.4.3.1 Target Disease Prevalence
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.3.5 Brazil Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4 Mexico
7.4.4.1 Target Disease Prevalence
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.4.5 Mexico Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5 Argentina
7.4.5.1 Target Disease Prevalence
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.5.5 Argentina Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6 Colombia
7.4.6.1 Target Disease Prevalence
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.6.5 Colombia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7 Chile
7.4.7.1 Target Disease Prevalence
7.4.7.2 Competitive Scenario
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.4.7.5 Chile Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.8 Rest Of Latam Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5 Middle East & Africa (MEA)
7.5.1 Swot Analysis
7.5.2 Key Regional Dynamics
7.5.2.1 Middle East & Africa Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3 South Africa
7.5.3.1 Target Disease Prevalence
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Reimbursement Scenario
7.5.3.5 South Africa Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4 Saudi Arabia
7.5.4.1 Target Disease Prevalence
7.5.4.2 Competitive Scenario
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.5.4.5 Saudi Arabia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5 UAE
7.5.5.1 Target Disease Prevalence
7.5.5.2 Competitive Scenario
7.5.5.3 Regulatory Framework
7.5.5.4 Reimbursement Scenario
7.5.5.5 UAE Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.6 Israel
7.5.6.1 Target Disease Prevalence
7.5.6.2 Competitive Scenario
7.5.6.3 Regulatory Framework
7.5.6.4 Reimbursement Scenario
7.5.6.5 Israel Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.7 Egypt
7.5.7.1 Target Disease Prevalence
7.5.7.2 Competitive Scenario
7.5.7.3 Regulatory Framework
7.5.7.4 Reimbursement Scenario
7.5.7.5 Egypt Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.8 Kuwait
7.5.8.1 Target Disease Prevalence
7.5.8.2 Competitive Scenario
7.5.8.3 Regulatory Framework
7.5.8.4 Reimbursement Scenario
7.5.8.5 Kuwait Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.9 Rest of MEA Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 REGENXBIO, INC.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 OXFORD BIOMEDICA PLC
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic Initiatives
8.1.3 VOYAGER THERAPEUTICS
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 HUMAN STEM CELLS INSTITUTE
8.1.4.1 Company overview
8.1.4.2 Product benchmarking
8.1.4.3 Strategic Initiatives
8.1.5 DIMENSION THERAPEUTICS, INC.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic Initiatives
8.1.6 BRISTOL-MYERS SQUIBB COMPANY
8.1.6.1 Company overview
8.1.6.1.1 Celgene Corporation
8.1.6.2 Financial performance (Bristol-Myers Squibb)
8.1.6.2.1 Financial performance (Celgene Corporation)
8.1.6.3 Product benchmarking (Bristol-Myers Squibb)
8.1.6.3.1 Product benchmarking (Celgene)
8.1.6.4 Strategic Initiatives
8.1.6.4.1 Strategic Initiatives
8.1.7 SANOFI
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic Initiatives
8.1.8 APPLIED GENETIC TECHNOLOGIES CORPORATION
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic Initiatives
8.1.9 F. HOFFMANN-LA ROCHE LTD.
8.1.9.1 Company overview
8.1.9.1.1 Spark Therapeutics, Inc.
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 BLUEBIRD BIO, INC.
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic Initiatives
8.1.11 NOVARTIS AG
8.1.11.1 Company overview
8.1.11.1.1 AveXis, Inc.
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic Initiatives
8.1.11.4.1 Strategic Initiatives
8.1.12 TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
8.1.12.1 Company overview
8.1.12.2 Product benchmarking
8.1.12.3 Strategic Initiatives
8.1.13 UNIQURE N.V.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic Initiatives
8.1.14 TAKEDA PHARMACEUTICAL COMPANY LIMITED
8.1.14.1 Company overview
8.1.14.2 Financial performance
8.1.14.3 Product benchmarking
8.1.14.4 Strategic Initiatives
8.1.15 CELLECTIS S.A.
8.1.15.1 Company overview
8.1.15.2 Financial performance
8.1.15.3 Product benchmarking
8.1.15.4 Strategic Initiatives
8.1.16 SANGAMO THERAPEUTICS, INC.
8.1.16.1 Company overview
8.1.16.2 Financial performance
8.1.16.3 Product benchmarking
8.1.16.4 Strategic Initiatives
8.1.17 ORCHARD THERAPEUTICS
8.1.17.1 Company overview
8.1.17.2 Financial performance
8.1.17.3 Product benchmarking
8.1.17.4 Strategic Initiatives
8.1.18 GILEAD LIFESCIENCES, INC.
8.1.18.1 Company overview
8.1.18.2 Financial Performance
8.1.18.3 Product benchmarking
8.1.18.4 Strategic Initiatives
8.1.19 BENITEC BIOPHARMA
8.1.19.1 Company overview
8.1.19.2 Financial Performance
8.1.19.3 Product benchmarking
8.1.19.4 Strategic Initiatives
8.1.20 SIBIONO GENETECH CO., LTD
8.1.20.1 Company overview
8.1.20.2 Product benchmarking
8.1.21 SHANGHAI SUNWAY BIOTECH CO., LTD.
8.1.21.1 Company overview
8.1.21.2 Product benchmarking
8.1.22 GENSIGHT BIOLOGICS S.A.
8.1.22.1 Company overview
8.1.22.2 Financial performance
8.1.22.3 Product benchmarking
8.1.22.4 Strategic initiatives
8.1.23 TRANSGENE
8.1.23.1 Company overview
8.1.23.2 Financial performance
8.1.23.3 Product benchmarking
8.1.23.4 Strategic initiatives
8.1.24 CALIMMUNE, INC.
8.1.24.1 Company overview
8.1.24.2 Product benchmarking
8.1.24.3 Strategic initiatives
8.1.25 EPEIUS BIOTECHNOLOGIES CORP.
8.1.25.1 Company overview
8.1.25.2 Product benchmarking
8.1.26 ASTELLAS PHARMA INC.
8.1.26.1 Company overview
8.1.26.2 Audentes Therapeutics, Inc.
8.1.26.2.1 Company overview
8.1.26.3 Financial performance
8.1.26.3.1 Financial performance
8.1.26.4 Product benchmarking
8.1.26.5 Strategic initiatives
8.1.27 AMERICAN GENE TECHNOLOGIES
8.1.27.1 Company overview
8.1.27.2 Product benchmarking
8.1.27.3 Strategic initiatives
8.1.28 BIOMARIN PHARMACEUTICALS, INC.
8.1.28.1 Company overview
8.1.28.2 Financial performance
8.1.28.3 Product benchmarking
8.1.28.4 Strategic initiatives

 

ページTOPに戻る


 

Summary

Gene Therapy Market Growth & Trends

The global gene therapy market is expected to reach USD 29.47 billion by 2030, registering a CAGR of 19.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Gene Therapy Market Report Highlights

• By vector type, the AAV segment is expected to grow rapidly during the forecast period. AAV is a popular vector for gene therapy, which accounts for a 24.0% share of the viral-vectored gene therapy studies conducted globally. During the last period, the number of clinical studies using AAV vectors has expanded swiftly

• Moreover, Retroviruses held a significant market share in 2022 owing to the ease of isolation and incorporation of DNA into the virus

• By indication, Spinal Muscular Atrophy (SMA) dominated the market. The development of Zolgensma has significantly proven its efficacy in the treatment of SMA, along with changing the disease phenotype. In May 2019, Novartis received approval from the FDA for Zolgensma, which is designed to address the root cause of SMA

• The inherited retinal diseases segment is expected to expand at the fastest CAGR in the forecast period owing to the increase in R&D activities for the development of genetic therapies used for treating ocular diseases, including inherited retinal disease. Luxturna is being commercialized by Spark therapeutics in the U.S. and by Novartis outside the U.S. as a treatment for a form of inherited retinal disease

• North America is a leading market in terms of revenue generated through clinical trials and a list of approved products. Considering factors such as a strong regulatory framework for stimulating the development of cellular therapy and the presence of a substantial number of biotechnology companies in the region, several sponsors and government agencies are making major investments

• Asia Pacific is anticipated to witness significant growth in the forecast period, which can be attributed to growing adoption rate of the genetic therapies, increased investment by the governments, and presence of key companies



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1 Executive Summary
1.1 Market Summary
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Model
2.3.1 Historic And Base Year Estimates
2.3.2 Forecast Analysis
2.3.3 Study Of Approved Therapies By Disease Incidence
2.3.4 Study Of Approved Therapies By Vector
2.3.5 Region-Wise Approval
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Robust Gene Therapy Pipeline
3.3.1.2 Introduction Of Technological Advancements
3.3.1.3 Increasing Investment From Companies And Partnerships
3.3.1.4 Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
3.3.2 Market Restraint Analysis
3.3.2.1 Absence Of Effective Diagnosis Framework
3.3.2.2 High Prices Of Gene Therapy
3.3.3 Market Opportunity Analysis
3.3.3.1 Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
3.3.3.2 Facility Expansion For Cell And Gene Therapies
3.3.3.3 Technological Advancements In Manufacturing Vectors
3.3.4 Challenge Analysis
3.3.4.1 Production capacity challenges
3.3.4.2 Manufacturing challenges about large-scale production of vectors
3.4 Regulatory Framework
3.5 Major Deals & Strategic Alliances Analysis
3.5.1 Mergers & Acquisitions
3.5.2 Collaborations & Partnerships
3.6 Pipeline Analysis
3.7 Payment & Pricing Models
3.7.1 Payment Models For Innovative Therapies
3.8 Swot Analysis, by factor (Political & legal, economic, and technological)
3.9 Porter’s Five Forces Analysis
3.10 Number of Gene Therapy Doses Sold in 2022
3.11 Number of Patients Treated with Gene Therapy, 2022
Chapter 4 COVID-19 Impact Analysis
4.1 Key Market Initiatives
4.2 Conclusion
Chapter 5 Indication Business Analysis
5.1 Gene Therapy Market: Indication Movement Analysis
5.2 Acute Lymphoblastic Leukemia (ALL)
5.2.1 Global Gene Therapy Market For Acute Lymphoblastic Leukemia (All), 2018 - 2030 (USD Million)
5.2.2 Global Acute Lymphoblastic Leukemia (All) Patients Treated With Gene Therapy, 2018 - 2030
5.3 Inherited Retinal Disease
5.3.1 Global Gene Therapy Market For Inherited Retinal Disease, 2018 - 2030 (USD Million)
5.3.2 Global Inherited Retinal Disease Patients Treated With Gene Therapy, 2018 - 2030
5.4 Large B-Cell Lymphoma
5.4.1 Global Gene Therapy Market For Large B-Cell Lymphoma, 2018 - 2030 (USD Million)
5.4.2 Global Large B-Cell Lymphoma Patients Treated With Gene Therapy, 2018 - 2030
5.5 Adenosine Deaminase (Ada)‐Deficient Severe Combined Immunodeficiency (Scid)
5.5.1 Global Gene Therapy Market For Ada-Scid, 2018 - 2030 (USD Million)
5.5.2 Global Ada-Scid Patients Treated With Gene Therapy, 2018 - 2030
5.6 Melanoma (Lesions)
5.6.1 Global Gene Therapy Market For Melanoma (Lesions), 2018 - 2030 (USD Million)
5.6.2 Global Melanoma (Lesions) Patients Treated With Gene Therapy, 2018 - 2030
5.7 Beta-Thalassemia Major/Sickle Cell Disease (Scd)
5.7.1 Global Gene Therapy Market For Beta Thalassemia Major/Sickle Cell Diseases, 2018 - 2030 (USD Million)
5.7.2 Global Beta Thalassemia Major/Sickle Cell Diseases Patients Treated With Gene Therapy, 2018 - 2030
5.8 Head & Neck Squamous Cell Carcinoma
5.8.1 Global Gene Therapy Market For Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
5.8.2 Global Head & Neck Squamous Cell Carcinoma Patients Treated With Gene Therapy, 2018 - 2030
5.9 Peripheral Arterial Disease
5.9.1 Global Gene Therapy Market For Peripheral Arterial Disease, 2018 - 2030 (USD Million)
5.9.2 Global Peripheral Arterial Disease Patients Treated With Gene Therapy, 2018 - 2030
5.10 Spinal Muscular Atrophy (Sma)
5.10.1 Global Gene Therapy Market For Spinal Muscular Atrophy (Sma), 2018 - 2030 (USD Million)
5.10.2 Global Spinal Muscular Atrophy (Sma) Patients Treated With Gene Therapy, 2018 - 2030
5.11 Others
Chapter 6 Vector Type Business Analysis
6.1 Gene Therapy Market: Vector Type Movement Analysis
6.2 Gene Therapy Market: Vector Movement Analysis
6.3 Lentiviral Vectors
6.3.1 Global Lentivirus-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.4 Adeno-Associated Viral (Aav) Vectors
6.4.1 Global Aav-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.5 Retrovirus Vectors
6.5.1 Global Retrovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.6 Modified Herpes Simplex Virus
6.6.1 Global Modified Herpes Simplex Virus Vectors -Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.7 Adenovirus Vectors
6.7.1 Global Adenovirus Vectors-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.8 Non-Viral Plasmid Vector
6.8.1 Global Non-Viral Plasmid Vector-Based Gene Therapy Market, 2018 - 2030 (USD Million)
6.9 Others
6.9.1 Global Others-Based Gene Therapy Market, 2018 - 2030 (USD Million)
Chapter 7 Regional Business Analysis
7.1 North America
7.1.1 Swot Analysis
7.1.1.1 North America Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2 Europe
7.2.1 Swot Analysis
7.2.1.1 Europe Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3 U.K.
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.10 Rest Of Europe Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3 Asia Pacific
7.3.1 Swot Analysis
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Target Disease Prevalence
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.2.5 Japan Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3 China
7.3.3.1 Target Disease Prevalence
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.3.5 China Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4 India
7.3.4.1 Target Disease Prevalence
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.4.5 India Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5 South Korea
7.3.5.1 Target Disease Prevalence
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.5.5 South Korea Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6 Australia
7.3.6.1 Target Disease Prevalence
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.6.5 Australia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7 Thailand
7.3.7.1 Target Disease Prevalence
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.7.5 Thailand Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8 Rest Of Asia Pacific Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4 Latin America
7.4.1 Swot Analysis:
7.4.2 Key Regional Dynamics
7.4.2.1 Latin America Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3 Brazil
7.4.3.1 Target Disease Prevalence
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.3.5 Brazil Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4 Mexico
7.4.4.1 Target Disease Prevalence
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.4.5 Mexico Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5 Argentina
7.4.5.1 Target Disease Prevalence
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.5.5 Argentina Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6 Colombia
7.4.6.1 Target Disease Prevalence
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.6.5 Colombia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7 Chile
7.4.7.1 Target Disease Prevalence
7.4.7.2 Competitive Scenario
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.4.7.5 Chile Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.8 Rest Of Latam Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5 Middle East & Africa (MEA)
7.5.1 Swot Analysis
7.5.2 Key Regional Dynamics
7.5.2.1 Middle East & Africa Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3 South Africa
7.5.3.1 Target Disease Prevalence
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Reimbursement Scenario
7.5.3.5 South Africa Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4 Saudi Arabia
7.5.4.1 Target Disease Prevalence
7.5.4.2 Competitive Scenario
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.5.4.5 Saudi Arabia Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5 UAE
7.5.5.1 Target Disease Prevalence
7.5.5.2 Competitive Scenario
7.5.5.3 Regulatory Framework
7.5.5.4 Reimbursement Scenario
7.5.5.5 UAE Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.6 Israel
7.5.6.1 Target Disease Prevalence
7.5.6.2 Competitive Scenario
7.5.6.3 Regulatory Framework
7.5.6.4 Reimbursement Scenario
7.5.6.5 Israel Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.7 Egypt
7.5.7.1 Target Disease Prevalence
7.5.7.2 Competitive Scenario
7.5.7.3 Regulatory Framework
7.5.7.4 Reimbursement Scenario
7.5.7.5 Egypt Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.8 Kuwait
7.5.8.1 Target Disease Prevalence
7.5.8.2 Competitive Scenario
7.5.8.3 Regulatory Framework
7.5.8.4 Reimbursement Scenario
7.5.8.5 Kuwait Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.9 Rest of MEA Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 REGENXBIO, INC.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 OXFORD BIOMEDICA PLC
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic Initiatives
8.1.3 VOYAGER THERAPEUTICS
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 HUMAN STEM CELLS INSTITUTE
8.1.4.1 Company overview
8.1.4.2 Product benchmarking
8.1.4.3 Strategic Initiatives
8.1.5 DIMENSION THERAPEUTICS, INC.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic Initiatives
8.1.6 BRISTOL-MYERS SQUIBB COMPANY
8.1.6.1 Company overview
8.1.6.1.1 Celgene Corporation
8.1.6.2 Financial performance (Bristol-Myers Squibb)
8.1.6.2.1 Financial performance (Celgene Corporation)
8.1.6.3 Product benchmarking (Bristol-Myers Squibb)
8.1.6.3.1 Product benchmarking (Celgene)
8.1.6.4 Strategic Initiatives
8.1.6.4.1 Strategic Initiatives
8.1.7 SANOFI
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic Initiatives
8.1.8 APPLIED GENETIC TECHNOLOGIES CORPORATION
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic Initiatives
8.1.9 F. HOFFMANN-LA ROCHE LTD.
8.1.9.1 Company overview
8.1.9.1.1 Spark Therapeutics, Inc.
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 BLUEBIRD BIO, INC.
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic Initiatives
8.1.11 NOVARTIS AG
8.1.11.1 Company overview
8.1.11.1.1 AveXis, Inc.
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic Initiatives
8.1.11.4.1 Strategic Initiatives
8.1.12 TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
8.1.12.1 Company overview
8.1.12.2 Product benchmarking
8.1.12.3 Strategic Initiatives
8.1.13 UNIQURE N.V.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic Initiatives
8.1.14 TAKEDA PHARMACEUTICAL COMPANY LIMITED
8.1.14.1 Company overview
8.1.14.2 Financial performance
8.1.14.3 Product benchmarking
8.1.14.4 Strategic Initiatives
8.1.15 CELLECTIS S.A.
8.1.15.1 Company overview
8.1.15.2 Financial performance
8.1.15.3 Product benchmarking
8.1.15.4 Strategic Initiatives
8.1.16 SANGAMO THERAPEUTICS, INC.
8.1.16.1 Company overview
8.1.16.2 Financial performance
8.1.16.3 Product benchmarking
8.1.16.4 Strategic Initiatives
8.1.17 ORCHARD THERAPEUTICS
8.1.17.1 Company overview
8.1.17.2 Financial performance
8.1.17.3 Product benchmarking
8.1.17.4 Strategic Initiatives
8.1.18 GILEAD LIFESCIENCES, INC.
8.1.18.1 Company overview
8.1.18.2 Financial Performance
8.1.18.3 Product benchmarking
8.1.18.4 Strategic Initiatives
8.1.19 BENITEC BIOPHARMA
8.1.19.1 Company overview
8.1.19.2 Financial Performance
8.1.19.3 Product benchmarking
8.1.19.4 Strategic Initiatives
8.1.20 SIBIONO GENETECH CO., LTD
8.1.20.1 Company overview
8.1.20.2 Product benchmarking
8.1.21 SHANGHAI SUNWAY BIOTECH CO., LTD.
8.1.21.1 Company overview
8.1.21.2 Product benchmarking
8.1.22 GENSIGHT BIOLOGICS S.A.
8.1.22.1 Company overview
8.1.22.2 Financial performance
8.1.22.3 Product benchmarking
8.1.22.4 Strategic initiatives
8.1.23 TRANSGENE
8.1.23.1 Company overview
8.1.23.2 Financial performance
8.1.23.3 Product benchmarking
8.1.23.4 Strategic initiatives
8.1.24 CALIMMUNE, INC.
8.1.24.1 Company overview
8.1.24.2 Product benchmarking
8.1.24.3 Strategic initiatives
8.1.25 EPEIUS BIOTECHNOLOGIES CORP.
8.1.25.1 Company overview
8.1.25.2 Product benchmarking
8.1.26 ASTELLAS PHARMA INC.
8.1.26.1 Company overview
8.1.26.2 Audentes Therapeutics, Inc.
8.1.26.2.1 Company overview
8.1.26.3 Financial performance
8.1.26.3.1 Financial performance
8.1.26.4 Product benchmarking
8.1.26.5 Strategic initiatives
8.1.27 AMERICAN GENE TECHNOLOGIES
8.1.27.1 Company overview
8.1.27.2 Product benchmarking
8.1.27.3 Strategic initiatives
8.1.28 BIOMARIN PHARMACEUTICALS, INC.
8.1.28.1 Company overview
8.1.28.2 Financial performance
8.1.28.3 Product benchmarking
8.1.28.4 Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

Grand View Research社の生物分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る